Xin Lang Cai Jing·2026-01-27 01:36Group 1 - The core viewpoint of the news is that Nocera Biopharma experienced a decline in stock price and significant trading activity, indicating high investor interest and potential volatility in the stock [1] - On January 26, Nocera Biopharma's stock fell by 2.02%, with a trading volume of 186 million yuan. The net financing purchase was 2.6452 million yuan, with a total financing and securities balance of 409 million yuan [1] - The financing balance of Nocera Biopharma is 408 million yuan, accounting for 7.66% of its market capitalization, which is above the 90th percentile of the past year, indicating a high level of leverage [1] Group 2 - Nocera Biopharma, established on November 3, 2015, focuses on the research, production, and commercialization of biopharmaceuticals, particularly in oncology and autoimmune diseases [2] - The company's revenue composition includes 87.67% from drug sales, 12.04% from technology licensing, and minimal contributions from testing and research services [2] - For the period from January to September 2025, Nocera Biopharma reported a revenue of 1.115 billion yuan, a year-on-year increase of 59.85%, while the net profit attributable to shareholders was -64.415 million yuan, reflecting a 76.61% year-on-year increase in losses [2] Group 3 - As of September 30, 2025, the top ten circulating shareholders of Nocera Biopharma include several new entrants, such as Wan Jia You Xuan and Ping An Medical Health, while some existing shareholders have reduced their holdings [3] - The sixth-largest shareholder, Fuguo Precision Medical Flexible Allocation Mixed A, decreased its holdings by 427,100 shares, while new shareholders have entered the top ten list [3]